Efek Samping Gastrointestinal pada Pasien Lansia Diabetes Melitus Tipe 2 Pengguna Metformin

Authors

  • Ega Putri Antasya Universitas Muhammadiyah Kudus
  • Eko Retnowati Universitas Muhammadiyah Kudus
  • Intan Adevia Rosnarita Universitas Muhammadiyah Kudus

DOI:

https://doi.org/10.31004/joecy.v6i2.10864

Keywords:

Metformin, Side effects, Type 2 Diabetes Mellitus, Gastrointestinal

Abstract

The high prevalence of type 2 diabetes mellitus in the elderly makes metformin a commonly used first-line therapy, although it is often associated with gastrointestinal side effects that can affect patient comfort and adherence. This study aimed to identify the characteristics of elderly patients, patterns of metformin use, the occurrence of gastrointestinal side effects, and to analyze the relationship between duration of use and the number of medications with these side effects. This was an analytical observational study with a cross-sectional approach conducted on outpatients at Sunan Kudus Islamic Hospital using purposive sampling. Data were collected from medical records and interviews and analyzed using the Mann–Whitney and Kruskal–Wallis tests. The results showed that most patients were aged 60–69 years with uncontrolled blood glucose levels, and commonly used metformin at a dose of 500 mg twice daily before meals, with a duration of use mostly 0–1 year and more combination therapy than monotherapy. Gastrointestinal side effects such as nausea, vomiting, diarrhea, abdominal pain, and bloating were mostly mild to moderate. There was a significant relationship between duration of use and vomiting (p=0.043), diarrhea (p=0.023), abdominal pain (p=0.019), and bloating (p=0.031), as well as between the number of medications and diarrhea (p=0.010), abdominal pain (p=0.003), and bloating (p=0.031). In conclusion, longer use of metformin and combination therapy increase the risk of gastrointestinal side effects, which may reduce comfort, lower adherence, and potentially worsen blood glucose control, so therapy optimization and regular monitoring are needed.

 

 

References

Adevia, I. (n.d.). metode penelitian konsep,desain, dan analisis data.

Alhara Yuwanda, Megi Maulina, Nopratilova, Ahda Sabila, R. A. (2025). Education on the Importance of Understanding the Impact and Side Effects of Metformin. 12, 3463–3472. Aoki, A., Mizu, D., Higashi, H., & Yamashita, J. (2026). Metformin-Associated Encephalopathy as a Rare but Serious Adverse Effect : A Case Report Case Presentation.

(1), 4–9. https://doi.org/10.7759/cureus.101758

Campagnoli, L. I. M., Varesi, A., Fahmideh, F., Hakimizad, R., Petkovic, P., Barbieri, A., Marchesi, N., & Pascale, A. (2025). From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin. International Journal of Molecular Sciences, 26(19), 1–46. https://doi.org/10.3390/ijms26199748

Care, D., & Suppl, S. S. (2024). Introduction and Methodology : Standards of Care in Diabetes

— 2024. 47(January), 1–4.

Chaker, F., Kallel, A., Khessairi, N., Yazidi, M., Oueslati, I., Chatti, H. A., Feki, M., & Chihaoui, M. (2025). Metformin efficacy and tolerance according to genetic polymorphisms of

organic cation transporter 1 in Tunisian patients with type 2 diabetes. Frontiers in Endocrinology, 16(June), 1–8. https://doi.org/10.3389/fendo.2025.1536402

Cicih, A., Aligita, W., & Susilawati, E. (2022). A Review: The pharmacokinetics and pharmacodynamics of metformin-herb interactions Review : Interaksi farmakokinetik dan farmakodinamik metformin-herbal. Jurnal Ilmiah Farmasi (Scientific Journal of Pharmacy), 18(1), 13–25. http://journal.uii.ac.id/index.php/JIF

Derosa, G., D’Angelo, A., Romano, D., & Maffioli, P. (2017). Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Design, Development and Therapy, 11, 1481–1488. https://doi.org/10.2147/DDDT.S131670

Febriyanti, A. P., Ramadhani, R., Atmaja, D., Oktaviani, H. C., Wijaya, D., Farmasi, P. S., Maulana, U. I. N., & Ibrahim, M. (2023). Analisis Peresepan Polifarmasi Pada Pasien Geriatri dengan Diabetes Melitus Tipe 2 Berdasarkan Beers Criteria 2023. 9(2), 613–620.

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe,

K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(17):6275. Published 2020 Aug 30. doi:10.3390/ijms21176275. International Journal of Molecular Sciences, 21(17), 1–34.

In, P., Therapy, M., Affecting, T. H. E., & At, F. (2023). Prevalensi Efek Samping Gangguan Gastrointestinal Terapi Metformin Pada Pasien DM Type 2 Dan Faktor Yang Mempengaruhinya Di Puskesmas Kecamatan Pasar Rebo Tahun 2020. 17(Dm), 1–9. https://doi.org/10.36082/qjk.v17i1.327

Kilwakit, A., & Bertorio, M. J. (2024). Kontrol glikemik dan analisis efek samping metformin dibandimgkan dengan kombinasi metformin-pioglitazone pada pasien diabetes melitus tipe 2 di rumah sakit x yogyakarta Diabetes melitus atau penyakit kencing manis adalah salah satu gangguan metabolisme kronis yang ditandai dengan adanya penigkatan kadar gula dalam darah , puasa dan vaskular Menurut Internasional diabetes federation tahun 2021 , bahwa Indonesia tinggi yaitu berada pada peringkat ke-5 di dunia setelah Cina , India , Pakistan dan prevalensi diabetes di Negara Indonesia sebesar 2 % angka tersebut mengalami dari Riskesdas diabetes melitus di Daerah Istimewa Yogyakarta sebesar 23 , 3 %. Diabetes melitus merupakan penyakit metabolik yang ditandai dengan tingginya kadar glukosa dalam darah . Penyebab diabetes melitus yaitu faktor genetik mengembangkan diabetes , pengelolaan dan pencegahan penyakit diabetes terbagi menjadi dua kategori utama , Penyakit penyerta mikrovaskular. 2(1), 45–53.

Lin, K., Wang, R., Li, T., Zuo, Y., Yang, S., Dong, D., & Zhu, Y. (2025). Drug Transporters and Metabolizing Enzymes in Antimicrobial Drug Pharmacokinetics : Mechanisms , Drug – Drug Interactions , and Clinical Implications.

Magister, S., Klinik, F., & Padjadjaran, U. (2023). Pengaruh Faktor Usia , Polifarmasi , dan Komorbiditas terhadap Drug- Related Problems pada Pasien Diabates Melitus Tipe 2 The Influence of Age , Polypharmacy , and Comorbidities on Drug-Related Problems in Patiens with Type 2 Diabetes Mellitus. 12(3). https://doi.org/10.15416/ijcp.2023.12.3.61902

Nabrdalik, K., Skonieczna-Żydecka, K., Irlik, K., Hendel, M., Kwiendacz, H., Łoniewski, I., Januszkiewicz, K., Gumprecht, J., & Lip, G. Y. H. (2022). Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. Frontiers in Endocrinology, 13(September), 1–17. https://doi.org/10.3389/fendo.2022.975912

Nursela, Leny, B., Natasari, I., & Furqani, N. (2025). Journal of pharmaceutical. 3(1), 22–29.

Pratama, A. (2025). Mekanisme Kerja Obat Anti Diabetes Golongan Biguanid Dan Sulfonilurea Tinjauan Kimia Medisinal. 9(20), 2981–2986.

Putri, A., Np, M., Untari, E. K., & Rizkifan, S. (n.d.). PENGARUH USIA PASIEN DAN DOSIS TERHADAP EFEK SAMPING METFORMIN PADA PASIEN DIABETES TIPE 2. 8(2), 51–56.

Rahayu, S., Julaiha, S., Ardini, D., May Indriyani Jurusan Farmasi, D., Kemenkes Tanjung Karang, P., & Lampung, B. (2024). Gambaran Efek Samping Obat Beradasarkan Usia, Cara Minum, danDosis Obat Metformin pada Penderita Diabetes Melitus Tipe 2. Journal of Pharmaceutical Sciences and Technology, 1(1), 7–16. https://ejurnal.poltekkes-tjk.ac.id/index.php/pj

Retnowati, E., & Lestari, D. R. (2022). he relationship of combination oral diabetic and hypertension to drug interactions in outpatients puskesmas hubungan kombinasi oral diabetes dan hipertensi terhadap interaksi obat pada pasien rawat jalan puskesmas kedung-1. 458–468.

Rongcai, R. E. N., Guoxiong, W. U., & Ming, C. A. I. (n.d.). metode penelitian kuantitatif kualitatif prof Dr. Sugiyono.

Sukirawati. (2025). Jurnal Kesehatan Yamasi Makassar. 9(1), 48–55.

Wardhany, F. K., Mukti, A. W., & Purbosari, I. (2024). EVALUASI RESEP POLIFARMASI PADA PASIEN GERIATRI YANG TERDIAGNOSA DIABETES MELITUS TIPE 2 ( PENELITIAN INI DILAKUKAN DI RSUD HAJI PROVINSI JAWA TIMUR ). 5(September), 8831–8847.

Widiasari, K. R., Wijaya, I. M. K., & Suputra, P. A. (2021). Widiasari, K. R., Wijaya, I.

M. K., & Suputra, P.a., (2021). Ganesha Medicine, 1(2), 114.

Wirayudha, S. A., Agusaputra, H., & Hernanda, P. Y. (2025). Analisis Karakteristik Pasien Diabetes Melitus Tipe 2 di Puskesmas Dukuh Kupang Surabaya. September.

Xie, C., Iroga, P., Bound, M. J., Grivell, J., Huang, W., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2024). Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study. Diabetologia, 67(7), 1260–1270. https://doi.org/10.1007/s00125-024-06131-6

Downloads

Published

30-05-2026

How to Cite

Antasya, E. P., Retnowati, E. ., & Rosnarita, I. A. . (2026). Efek Samping Gastrointestinal pada Pasien Lansia Diabetes Melitus Tipe 2 Pengguna Metformin. Journal of Innovative and Creativity, 6(2), 28605–28611. https://doi.org/10.31004/joecy.v6i2.10864

Issue

Section

Articles